NovelStem International Corp.
NSTM
Other OTC0.01
USD
- -
- -
CIK
0000912544
ISIN
US67001V1098
CUSIP
67001V109
Return %
Stock
S&P500
1Y
-75.00
26.84
3Y
-95.78
77.03
5Y
-96.87
80.55
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- CEO
- Jan H. Loeb
- Sector
- Healthcare
- Industry
- Medical - Diagnostics & Research
- Address
- 2255 Glades Road Boca Raton FL United States of America 33431
- IPO Date
- Nov 12, 1993
- CIK
- 0000912544
- Website
- novelstem.com
- Similar Companies
- Business
- NovelStem International Corp. is a biotechnology company specializing in the development and commercialization of stem cell-based diagnostic technology aimed at predicting patients' resistance to chemotherapy, thereby enabling more targeted and effective cancer treatments. Its core products and services include haploid human embryonic stem cell-based genetic screenings and diagnostic solutions designed to identify genes responsible for resistance to anti-cancer drugs. The company operates primarily in the biotechnology and cancer therapeutics industry, leveraging proprietary bio-platforms for precision oncology drug development and diagnostics. Headquartered in Boca Raton, Florida, NovelStem was founded in 2018 and maintains a significant interest in NewStem Ltd., an Israeli biotech firm focused on stem cell technology applications in oncology and genetic research. In recent strategic developments within the last two years, NovelStem has undergone significant repositioning, including the sale of its 50% interest in the Netco Partners joint venture, which generated proceeds used to extinguish approximately $3 million in litigation funding debt. The company announced a strategic focus on seeking a merger partner to enhance shareholder value and improve its financial position, with ongoing efforts to reduce debt and bolster cash reserves. NovelStem's ownership interest in NewStem, which has developed stem cell-based diagnostic and therapeutic platforms, was increased to 33%, although NewStem ceased operations in late 2024 due to funding constraints, resulting in the liquidation of its assets and reversion of key technology licenses back to the original licensor. The company has also engaged in collaborations to validate and commercialize its diagnostic software platform to advance cancer treatment efficacy. NovelStem's industry focus encompasses biotechnology research in stem cells, genetic cancer resistance diagnostics, and precision oncology. The company serves global markets with its innovative diagnostic solutions and has recently shifted from media-related business activities to concentrate fully on biotechnology and life sciences innovation. Its recent operational and financial actions position the company for potential strategic mergers while continuing to leverage patented genetic platform technologies for anti-cancer therapies and diagnostics.
NovelStem International (OTCMKTS:NSTM) and Halozyme Therapeutics (NASDAQ:HALO) Head to Head Contrast
Arbitration Confirms NovelStem Joint Venture's Rights to Exploit 'Tom Clancy's Net Force' Franchise Globally via Film, TV, Online, Streaming, Gaming and Merchandising